Cover ImageSALE
Market Research Report

Autism Spectrum Disorder (ASD) - Market Insights, Epidemiology and Market Forecast-2027

Published by DelveInsight Business Research LLP Product code 751744
Published Content info 157 Pages
Delivery time: 1-2 business days
Price
Back to Top
Autism Spectrum Disorder (ASD) - Market Insights, Epidemiology and Market Forecast-2027
Published: December 1, 2018 Content info: 157 Pages
Description

DelveInsight's Autism Spectrum Disorder (ASD) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Autism Spectrum Disorder (ASD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Autism Spectrum Disorder (ASD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Autism Spectrum Disorder (ASD) - Disease Understanding and Treatment Algorithm

Autism Spectrum Disorder (ASD) is a developmental disorder that affects communication and behavior. Although autism can be diagnosed at any age, it is said to be a "developmental disorder" because symptoms generally appear in the first two years of life. ASD refers to a group of neurodevelopmental conditions defined by impairment in three areas: social interaction, communication or use of verbal and non-verbal language, and a stereotyped, restricted or repetitive pattern of behavior, interests and activities.

Autism Spectrum Disorder (ASD) is used to be called as Pervasive Developmental Disorder (PDD). PDD included five types or categories: Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder, Rett's Syndrome, and pervasive developmental Disorder-Not Otherwise Specified (PDD-NOS).

The DelveInsight Autism Spectrum Disorder (ASD) market report gives the thorough understanding of the ASD by including details such as disease definition, classification, Etiology, Pathophysiology, Signs and Symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Autism Spectrum Disorder (ASD) in the US, Europe, and Japan.

Autism Spectrum Disorder Epidemiology

The Autism Spectrum Disorder epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD), Gender Specific Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD) and Subtype-Specific Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD)] scenario of ASD in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

As per the study conducted by Guifeng Xu et al., titled as "Prevalence of Autism Spectrum Disorder among US Children and Adolescents, 2014-2016", the estimated prevalence for Autism Spectrum Disorder was 2.47% among US children and adolescents in 2014-2016, with no statistically significant increase over the 3 years. The observed prevalence was higher than estimates in previous years from the ADDM, although differences in study design and participant characteristics may partly explain the prevalence differences.

The total 7MM prevalent cases of Autism Spectrum Disorder in 2016 were 6,545,050 out of which the highest prevalent cases of this disease were seen in the United States, which accounted for approximately 57% of the total prevalent cases. The EU5 countries accounted for 1,715,717 cases as a whole in 2016. Japan had 1,094,393 cases in 2016, which accounted for approximately 17% of the total 7MM prevalent cases of Autism Spectrum Disorder. The total prevalent cases of ASD in 7MM is calculated by adding the prevalent cases of the individual country.

According to DelveInsight, total prevalent population of Autism Spectrum Disorder (ASD) in the 7 major markets is estimated approximately 6,545,050 cases in 2016 and it is expected to be change during the forecasted period (2016-2027).

DelveInsight estimates that the prevalent population of Autism Spectrum Disorder (ASD) in 7MM is expected to change for the study period 2016-2027.

DelveInsight estimates suggest higher prevalence of Autism Spectrum Disorder (ASD) in the United States with 3,734,939 cases in 2016.

Autism Spectrum Disorder Drug Chapters

This segment of the Autism Spectrum Disorder (ASD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The current therapeutic market for Autism Spectrum Disorder (ASD) is being dependent on the two FDA approved products including Johnson's Risperdal and Otsuka's Abilify and one EMA approved Neurim's Slenyto. Other off-label" therapies are also being used to improve the signs and symptoms of the disease. Drugs commonly prescribed to Autism Spectrum Disorder (ASD) patients include antipsychotics, antidepressants, selective-serotonin reuptake inhibitors, stimulants, anticonvulsants, antihypertensives, CNS depressants and others.

Key players such as Roche, Neurochlore/Servier, Optinose, Yamo Pharmaceuticals, Curemark, etc. are developing emerging therapies for the treatment of patients with Autism Spectrum Disorder (ASD). Expected launch of emerging therapies such as Balovaptan (Roche), Bumetanide (Neurochlore/Servier), OPN-300 (Optinose), L1-79 (Yamo Pharmaceuticals), CM-AT (Curemark), are expected to increase the market size of ASD in upcoming years.

Autism Spectrum Disorder (ASD) Market Outlook

The Autism Spectrum Disorder (ASD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Autism Spectrum Disorder (ASD) in 7MM was found to be USD 2510.2 million in 2016, and is expected to increase from 2016-2027.

The United States accounts for the largest Autism Spectrum Disorder (ASD) market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

Autism Spectrum Disorder (ASD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Autism Spectrum Disorder (ASD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Autism Spectrum Disorder (ASD) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

ASD Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Autism Spectrum Disorder (ASD) market
  • Organize sales and marketing efforts by identifying the best opportunities for Autism Spectrum Disorder (ASD) market
  • To understand the future market competition in the Autism Spectrum Disorder (ASD) market.
Table of Contents
Product Code: DIMI0481

Table of Contents

1. Key Insights

2. Autism Spectrum Disorder Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of ASD in 2016
  • 2.2. Market Share (%) Distribution of ASD in 2027

3. Disease Overview: Autism Spectrum Disorder

  • 3.1. Introduction
  • 3.2. Types of ASD
  • 3.3. Etiology of Autism Spectrum Disorder
  • 3.4. Pathophysiology of Autism Spectrum Disorder
  • 3.5. Signs and Symptoms
  • 3.6. Diagnosis
  • 3.7. Diagnostic Guidelines
    • 3.7.1. Diagnostic Criteria
    • 3.7.2. American Academy of Neurology and the Child Neurology Society
    • 3.7.3. The National Institute for Health and Care Excellence (NICE)
  • 3.8. Diagnostic Algorithm

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Diagnosed Prevalent Cases of Autism Spectrum Disorder

5. Country Wise-Epidemiology of Autism Spectrum Disorder

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Diagnosed Prevalent Cases of ASD in the United States
    • 5.1.3. Gender Specific Diagnosed Prevalent cases of ASD in the United States
    • 5.1.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in the United States
  • 5.2. EU5
  • 5.3. Germany
    • 5.3.1. Assumptions and Rationale
    • 5.3.2. Diagnosed Prevalent Cases of ASD in Children in Germany
    • 5.3.3. Gender Specific Diagnosed Prevalent Cases of ASD in Germany
    • 5.3.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in Germany
  • 5.4. France
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Diagnosed Prevalent Cases of ASD in France
    • 5.4.3. Gender Specific Diagnosed Prevalent Cases of ASD in France
    • 5.4.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in France
  • 5.5. Italy
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Diagnosed Prevalent Cases of ASD in Italy
    • 5.5.3. Gender Specific Diagnosed Prevalent Cases of ASD in Italy
    • 5.5.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in Italy
  • 5.6. Spain
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Diagnosed Prevalent Cases of ASD in Spain
    • 5.6.3. Gender Specific Diagnosed Prevalent Cases of ASD in Spain
    • 5.6.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in Spain
  • 5.7. United Kingdom
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Diagnosed Prevalent Cases of ASD in the United Kingdom
    • 5.7.3. Gender Specific Diagnosed Prevalent Cases of ASD in the United Kingdom
    • 5.7.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in the United Kingdom
  • 5.8. Japan
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Diagnosed Prevalent Cases of ASD in Japan
    • 5.8.3. Gender Specific Diagnosed Prevalent Cases of ASD in Japan
    • 5.8.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in Japan

6. Treatment Practices

7. Treatment Guidelines and Recommendations

  • 7.1. American Academy of Child & Adolescent Psychiatry
  • 7.2. National Institute for Health and Care Excellence (NICE)

8. Treatment Algorithm

9. Unmet Needs

10. Marketed Drugs

  • 10.1. Risperdal: Johnson and Johnson
    • 10.1.1. Drug Description
    • 10.1.2. Regulatory Milestones
    • 10.1.3. Advantages & Disadvantages
    • 10.1.4. Clinical Development
    • 10.1.5. Safety and Efficacy
    • 10.1.6. Product Profile
  • 10.2. Abilify: Otsuka Pharmaceutical
    • 10.2.1. Drug Description
    • 10.2.2. Regulatory Milestones
    • 10.2.3. Advantages & Disadvantages
    • 10.2.4. Clinical Development
    • 10.2.5. Safety and Efficacy
    • 10.2.6. Product Profile
  • 10.3. Slenyto: Neurim Pharmaceuticals
    • 10.3.1. Drug Description
    • 10.3.2. Regulatory Milestones
    • 10.3.3. Advantages & Disadvantages
    • 10.3.4. Clinical Development
    • 10.3.5. Safety and Efficacy
    • 10.3.6. Product Profile

11. Emerging Therapies

  • 11.1. Key cross competition- Emerging Therapies
  • 11.2. Balovaptan: Roche
    • 11.2.1. Product Description
    • 11.2.2. Other Developmental Activities
    • 11.2.3. Clinical Development
    • 11.2.4. Safety and Efficacy
    • 11.2.5. Product Profile
  • 11.3. Bumetanide: Neurochlore/Servier
    • 11.3.1. Product Description
    • 11.3.2. Other Developmental Activities
    • 11.3.3. Clinical Development
    • 11.3.4. Safety and Efficacy
    • 11.3.5. Product Profile
  • 11.4. CM-AT: Curemark
    • 11.4.1. Product Description
    • 11.4.2. Other Developmental Activities
    • 11.4.3. Clinical Development
    • 11.4.4. Safety and Efficacy
    • 11.4.5. Product Profile
  • 11.5. L1-79: Yamo Pharmaceuticals
    • 11.5.1. Product Description
    • 11.5.2. Other Developmental Activities
    • 11.5.3. Clinical Development
    • 11.5.4. Safety and Efficacy
    • 11.5.5. Product Profile

12. Autism Spectrum Disorder: 7 Major Market Analysis

  • 12.1. Key Findings
  • 12.2. Market Size of Autism Spectrum Disorder in 7MM

13. Market Outlook by Country

14. The United States: Market Outlook

    • 14.1.1. United States Market Size
    • 14.1.2. Total Market size of Autism Spectrum Disorder
    • 14.1.3. Autism Spectrum Disorder Market by Therapies

15. EU-5 Countries: Market Outlook

  • 15.1. Germany
    • 15.1.1. Total Market size of Autism Spectrum Disorder
    • 15.1.2. Autism Spectrum Disorder Market by Therapies
  • 15.2. France
    • 15.2.1. Total Market size of Autism Spectrum Disorder
    • 15.2.2. Autism Spectrum Disorder Market by Therapies
  • 15.3. Italy
    • 15.3.1. Total Market size of Autism Spectrum Disorder
    • 15.3.2. Autism Spectrum Disorder Market by Therapies
  • 15.4. Spain
    • 15.4.1. Total Market size of Autism Spectrum Disorder
    • 15.4.2. Autism Spectrum Disorder Market by Therapies
  • 15.5. United Kingdom
    • 15.5.1. Total Market size of Autism Spectrum Disorder
    • 15.5.2. Autism Spectrum Disorder Market by Therapies

16. Japan: Market Outlook

  • 16.1. Total Market size of Autism Spectrum Disorder
  • 16.2. Autism Spectrum Disorder Market by Therapies

17. Market Drivers

18. Market Barriers

19. Appendix

  • 19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Tables

  • Table 1: Single gene disorders with the high rate of autism
  • Table 2: Changes in the diagnostic criteria for the PDDs in the DSM-5 (adapted from Ozonoff)
  • Table 3: Differential diagnosis of language disorders
  • Table 4: Severity Levels of Autism Spectrum Disorder
  • Table 5: Severity Levels of Autism Spectrum Disorder
  • Table 6: Organisation and delivery of care
  • Table 7: NICE Guideline, Core Autism Features
  • Table 8: 7MM Total Diagnosed Prevalent Cases of Autism Spectrum Disorder (2016-2027)
  • Table 9: Diagnosed Prevalent Cases of ASD in the United States (2016-2027)
  • Table 10: Gender Specific Diagnosed Prevalent Cases of ASD in the United States (2016-2027)
  • Table 11: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United States (2016-2027)
  • Table 12: Diagnosed Prevalent Cases of Autism Spectrum Disorder in Germany (2016-2027)
  • Table 13: Gender Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027)
  • Table 14: Subtype-Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027)
  • Table 15: Diagnosed Prevalent Cases of Autism Spectrum Disorder in France (2016-2027)
  • Table 16: Gender Specific Diagnosed Prevalent Cases of ASD in France (2016-2027)
  • Table 17: Subtype-Specific Diagnosed Prevalent Cases of ASD in France (2016-2027)
  • Table 18: Diagnosed Prevalent Cases of ASD in Italy (2016-2027)
  • Table 19: Gender Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027)
  • Table 20: Subtype-Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027)
  • Table 21: Diagnosed Prevalent Cases of ASD in Spain (2016-2027)
  • Table 22: Gender Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027)
  • Table 23: Subtype-Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027)
  • Table 24: Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027)
  • Table 25: Gender Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027)
  • Table 26: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027)
  • Table 27: Diagnosed Prevalent Cases of ASD in Japan (2016-2027)
  • Table 28: Gender Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027)
  • Table 29: Subtype-Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027)
  • Table 30: Essential characteristics of effective interventions for children with autism spectrum disorder
  • Table 31: Consensus recommendations of pharmacological treatment of co-occurring conditions and symptoms in children and adults with ASD
  • Table 32: Recommendations
  • Table 33: Antipsychotic medication for behaviour that challenges
  • Table 34: Sleep problems
  • Table 35: What is needed to inform the families in care?
  • Table 36: Key points for the general paediatrician
  • Table 37: Risperdal, Clinical Trial Description, 2018
  • Table 38: Abilify, Clinical Trial Description, 2018
  • Table 39: Slenyto, Clinical Trial Description, 2018
  • Table 40: Key cross competition- Emerging Therapies
  • Table 41: Balovaptan, Clinical Trial Description, 2018
  • Table 42: Bumetanide, Clinical Trial Description, 2018
  • Table 43: CM-AT, Clinical Trial Description, 2018
  • Table 44: L1-79, Clinical Trial Description, 2018
  • Table 45: 7 Major Market Size of Autism Spectrum Disorder in USD Million (2016-2027)
  • Table 46: United States Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Table 47: United States Market Size of ASD by Therapies in USD Million (2016-2027)
  • Table 48: Germany Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Table 49: Germany Market Size of ASD by Therapies in USD Million (2016-2027)
  • Table 50: France Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Table 51: France Market Size of ASD by Therapies in USD Million (2016-2027)
  • Table 52: Italy Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Table 53: Italy Market Size of ASD by Therapies in USD Million (2016-2027)
  • Table 54: Spain Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Table 55: Spain Market Size of ASD by Therapies in USD Million (2016-2027)
  • Table 56: United Kingdom Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Table 57: UK Market Size of ASD by Therapies in USD Million (2016-2027)
  • Table 58: Japan Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Table 59:Japan Market Size of ASD by Therapies in USD Million (2016-2027)

List of Figures

  • Figure 1: Types of Autism Spectrum Disorder
  • Figure 2: Converging Mechanisms of Autism Spectrum Disorder
  • Figure 3: Types of Autism Spectrum Disorder
  • Figure 4: 7MM Total Diagnosed Prevalent Cases of Autism Spectrum Disorder (2016-2027)
  • Figure 5: Diagnosed Prevalent Cases of ASD in the United States (2016-2027)
  • Figure 6: Gender Specific Diagnosed Prevalent Cases of ASD in the United States (2016-2027)
  • Figure 7: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United States (2016-2027)
  • Figure 8: Diagnosed Prevalent Cases of Autism Spectrum Disorder in Germany (2016-2027)
  • Figure 9: Gender Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027)
  • Figure 10: Subtype-Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027)
  • Figure 11: Diagnosed Prevalent Cases of Autism Spectrum Disorder in France (2016-2027)
  • Figure 12: Gender Specific Diagnosed Prevalent Cases of ASD in France (2016-2027)
  • Figure 13: Subtype-Specific Diagnosed Prevalent Cases of ASD in France (2016-2027)
  • Figure 14: Diagnosed Prevalent Cases of ASD in Italy (2016-2027)
  • Figure 15: Gender Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027)
  • Figure 16: Subtype-Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027)
  • Figure 17: Diagnosed Prevalent Cases of ASD in Spain (2016-2027)
  • Figure 18: Gender Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027)
  • Figure 19: Subtype-Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027)
  • Figure 20: Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027)
  • Figure 21: Gender Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027)
  • Figure 22: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027)
  • Figure 23: Diagnosed Prevalent Cases of ASD in Japan (2016-2027)
  • Figure 24: Gender Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027)
  • Figure 25: Subtype-Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027)
  • Figure 26: Unmet Needs for Autism Spectrum Disorder
  • Figure 27: 7 Major Market Size of Autism Spectrum Disorder in USD Million (2016-2027)
  • Figure 28: United States Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Figure 29: United States Market Size of ASD by Therapies in USD Million (2016-2027)
  • Figure 30: Germany Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Figure 31: Germany Market Size of ASD by Therapies in USD Million (2016-2027)
  • Figure 32: France Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Figure 33: France Market Size of ASD by Therapies in USD Million (2016-2027)
  • Figure 34: Italy Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Figure 35: Italy Market Size of ASD by Therapies in USD Million (2016-2027)
  • Figure 36: Spain Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Figure 37: Spain Market Size of ASD by Therapies in USD Million (2016-2027)
  • Figure 38: United Kingdom Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Figure 39: UK Market Size of ASD by Therapies in USD Million (2016-2027)
  • Figure 40: Japan Market Size of Autism Spectrum Disorder in USD Millions (2016-2027)
  • Figure 41: Japan Market Size of ASD by Therapies in USD Million (2016-2027)
  • Figure 42: Market Drivers
  • Figure 43:Market Barriers
Back to Top